Investors in TG Therapeutics (NASDAQ:TGTX) Have Seen Splendid Returns of 185% Over the Past Five Years
Investors in TG Therapeutics (NASDAQ:TGTX) Have Seen Splendid Returns of 185% Over the Past Five Years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the TG Therapeutics, Inc. (NASDAQ:TGTX) share price has soared 185% in the last half decade. Most would be very happy with that. It's also good to see the share price up 38% over the last quarter.
當你買入一家公司的股票時,值得注意的是它可能會失敗,你可能會損失資金。但當你選擇一家真正繁榮的公司時,你可能會獲得超過100%的回報。例如,TG Therapeutics, Inc. (納斯達克:TGTX)的股價在過去五年中 soared 185%。大多數人對此會非常滿意。看到股價在過去一個季度上漲了38%也是件好事。
Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.
現在值得關注一下公司的基本面,因爲這將幫助我們判斷長期股東回報是否與基礎業務的表現相匹配。
Because TG Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
由於TG Therapeutics在過去十二個月中出現了虧損,我們認爲市場可能更關注營業收入和收入增長,至少目前是如此。虧損公司的股東通常希望看到強勁的營業收入增長。正如你想象的那樣,持續的快速營業收入增長通常會帶來快速的利潤增長。
In the last 5 years TG Therapeutics saw its revenue grow at 86% per year. That's well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 23% per year, compound, during the period. This suggests the market has well and truly recognized the progress the business has made. TG Therapeutics seems like a high growth stock - so growth investors might want to add it to their watchlist.
在過去五年中,TG Therapeutics的營業收入每年增長86%。這遠高於大多數尚未盈利的公司。與此同時,考慮到其股價在此期間以23%的複合年增長率增長,其股價表現無疑反映了強勁的增長。這表明市場已經充分認識到該業務取得的進展。TG Therapeutics看起來像是一隻高增長股票,因此成長型投資者可能希望將其加入自選。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到盈利和營業收入隨時間的變化(通過點擊圖片發現確切值)。
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
您可以通過這個免費的互動圖形查看其資產負債表隨時間的增強(或減弱)。
A Different Perspective
不同的視角
It's nice to see that TG Therapeutics shareholders have received a total shareholder return of 84% over the last year. That gain is better than the annual TSR over five years, which is 23%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It's always interesting to track share price performance over the longer term. But to understand TG Therapeutics better, we need to consider many other factors. Even so, be aware that TG Therapeutics is showing 1 warning sign in our investment analysis , you should know about...
很高興看到TG Therapeutics的股東在過去一年中獲得了84%的總股東回報。這一增長好於過去五年的年化總股東回報率23%。因此,似乎最近對公司的情緒是積極的。在最好的情況下,這可能暗示着一些真正的業務勢頭,意味着現在可能是進一步深入了解的好時機。長期跟蹤股價表現總是很有趣。但要更好地理解TG Therapeutics,我們需要考慮許多其他因素。儘管如此,請注意,TG Therapeutics在我們的投資分析中顯示出一個警告信號,你應該知道……
But note: TG Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:TG Therapeutics可能不是最好的買入股票。所以請查看這份免費的有趣公司名單,這些公司過去有盈利增長(並且有進一步的增長預測)。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。
譯文內容由第三人軟體翻譯。